Evaluation of bromodeoxyuridine labeling in hepatomegaly produced by peroxisomal proliferation or P-450 induction in rodents.
Smith
P F
PF
O'Brien
K A
KA
Keenan
K P
KP
D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology*; D001973:Bromodeoxyuridine; D002455:Cell Division / Q000187:drug effects*; D003577:Cytochrome P-450 Enzyme System / Q000096:biosynthesis*; D004790:Enzyme Induction; D005260:Female; D006529:Hepatomegaly / Q000139:chemically induced* / Q000473:pathology; D008099:Liver / Q000187:drug effects / Q000201:enzymology / Q000473:pathology*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D008830:Microbodies / Q000187:drug effects / Q000648:ultrastructure*; D010634:Phenobarbital / Q000633:toxicity*; D011743:Pyrimidines / Q000633:toxicity*; D051381:Rats; D011919:Rats, Inbred Strains; D012016:Reference Values
D000924:Anticholesteremic Agents; D011743:Pyrimidines; C006253:pirinixic acid; D003577:Cytochrome P-450 Enzyme System; D001973:Bromodeoxyuridine; D010634:Phenobarbital